Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor: early-phase trial registry
104 of 197 indexed Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #53 of 28,707 conditions by registered trial count.
197 US clinical trials · 104 currently recruiting · #53 of 28,707 conditions by registered trial count
Solid Tumor: 197 US clinical trials tracked, 104 recruiting.
Solid Tumor is the subject of 197 registered US clinical trials on ClinicalTrials.gov, 104 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 165 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition solid-tumor
OPEN 104 | RECR 53% | LATE 4 | EARLY 165 | RANK #53 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Metastatic Breast Cancer (53% recruiting · 140 trials)
Solid Tumor lists 104 open slots (53% of 197 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor is recruiting above its size-band peers.
104 of 197 indexed trials (52.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumor trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 11 of 197 trials (5.6%). 149 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor enrolment sits around 80 participants.
Median target enrolment is 80 among the 197 trials that report a genuine target (sentinel values excluded). 108 of those (54.8%) plan for fewer than 100 participants.
-
Solid Tumor research is mostly interventional.
179 interventional and 18 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
197 total, page 2 of 4
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America
NCT06526819
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune
NCT06425926
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
PAQ Therapeutics
NCT06797336
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
NCT04903873
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis
NCT06014502
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences
NCT06452160
Dabrafenib and/or Trametinib Rollover Study
Novartis Pharmaceuticals
NCT03340506
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Inova Health Care Services
NCT06106360
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
St. Jude Children's Research Hospital
NCT06579469
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Biohaven Therapeutics
NCT06874335
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co
NCT05244551
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Alyssum Therapeutics
NCT06234098
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Axcynsis Therapeutics Pte
NCT06809114
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
NCT06952010
Study of STP938 in Advanced Solid Tumours
Step Pharma, SAS
NCT06297525
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Lamassu Bio
NCT06578624
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics
NCT05269316
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
NCT06010342
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
Washington University School of Medicine
NCT06689800
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
NCT05512208
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
Emory University
NCT04469530
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Qualigen Theraputics
NCT06086522
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
NCT06401356
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings
NCT04196257
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
University of California, San Diego
NCT07222631
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05985161
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Tyra Biosciences
NCT06160752
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics
NCT05144698
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
NCT07382544
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Children's National Research Institute
NCT05238792
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
NCT06563375
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics
NCT06398418
Concurrent Azeliragon With Craniospinal Irradiation
NYU Langone Health
NCT06724926
Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
Stanford University
NCT05206942
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
NCT03016806
Trial of DFP-14927 in Advanced Solid Tumors
Delta-Fly Pharma
NCT03943004
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Proviva Therapeutics
NCT06190886
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience
NCT06801002
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
St. Jude Children's Research Hospital
NCT05645523
Ex Vivo Expansion (ACT-X)
Mayo Clinic
NCT07137312
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
NCT05661201
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
NCT04796012
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
NCT05338658
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Miller Children's & Women's Hospital Long Beach
NCT02446431
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin
NCT06441331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 150 |
| Phase 2 | 15 |
| Phase 3 | 1 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor page
197 registered trials, 104 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 104 Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor condition card totals 197 registered trials; most-linked intervention Nivolumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.